Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2)

Oral Oncology

Volumn 70, Issue , 2017, Pages 65-72

  Rueda, A ^a   Giralt, J ^b   Manos M ^b   Lozano, A ^a   Sistiaga, A ^c   Garcia Miragall E ^d   Cacicedo, J ^e   Esteban, F ^f   Scola, B ^g   Contreras, J ^h   Ruiz, A ⁱ   Carral, A ^j   Sanchez Aniceto, G ⁱ   Pastor, M ^k   Herranz, J J ^l   Bernal, M ^m   Mesia R ^b  

^a HOSPITAL COSTA DEL SOL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j Hospital Lucus Augusti   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l HOSPITAL JUAN CANALEJO   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Clinical guidelines; Delphi methodology; Head and neck cancer; Spanish multidisciplinary consensus

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL EVALUATION; CONSENSUS; DELPHI STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SECOND CANCER; TREATMENT RESPONSE; HEAD AND NECK TUMOR; PATHOLOGY; SPAIN; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CONSENSUS; DELPHI TECHNIQUE; HEAD AND NECK NEOPLASMS; HUMANS; SPAIN;

EID: 85017420259     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2017.04.005     Document Type: Review

References (78)

1. Maños M, Girald J, Rueda A, Mesía R. Comprehensive treatment of the head and neck squamous cell carcinoma: first expert consensus from the Spanish society for head and neck cancer (part 1).
2. Clavel, S., Charron, M.P., Despres, P., The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 82 (2012), 567–573.
3. Liauw, S.L., Mancuso, A.A., Amdur, R.J., Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol 24 (2006), 1421–1427.
4. National Comprehensive Cancer Network: Head and Neck Cancer. V2.2016. < http://oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf>.
5. Montal, R., Oliva, Mesia, R., Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab. Clin Transl Oncol 18:11 (2016), 1140–1146.
6. Yao, M.M.D.P., Luo, P.M.D.P., Hoffman, H.T., Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clini Oncol 30 (2007), 264–270.
7. Brkovich, V.S., Miller, F.R., Karnad, A.B., The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope 116 (2006), 855–858.
8. Ong, S.C., Schoder, H., Lee, N.Y., Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 49 (2008), 532–540.
9. Mehanna, H., Wong, W.L., Dunn, J., PET-NECK trial management group. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 374:15 (2016), 1444–1454.
10. Lango, M.N., Myers, J.N., Garden, A.S., Controversies in surgical management of the node-positive neck after chemoradiation. Semin Radiat Oncol 19 (2009), 24–28.
11. Lau, H., Phan, T., Mackinnon, J., Matthews, T.W., Absence of planned neck dissection for the N2–N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Heard Neck Surg 134 (2008), 257–261.
12. Corry, J., Peters, L., Fisher, R., N2–N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders: Results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 30 (2008), 737–742.
13. Wee, J.T., Anderson, B.O., Corry, J., Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10 (2009), 1086–1092.
14. Lavertu, P., Bonafede, J.P., Adelstein, D.J., Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 124 (1998), 401–406.
15. Christopoulos, A., Nguyen-Tan, P.F., Tabet, J.C., Neck dissection following concurrent chemoradiation for advanced head and neck carcinoma: pathologic findings and complications. J Otolaryngol Head Neck Surg 37 (2008), 452–456.
16. Argiris, A., Kramouzis, M.V., Ferris, R.L., Head and neck cancer. Lancet 371 (2008), 1695–1709.
17. Marur, S., Forastiere, A.A., Head and neck cancer: changing epidemiology, diagnosis and treatment. Mayo Clin Proc 83 (2008), 489–501.
18. Goodwin, W.J., Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?. Laryngoscope 110:3 Pt 2 Suppl. 93 (2000), 1–18.
19. Janot, F., de Raucort, D., Bourhis, J., Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26 (2008), 5518–5523.
20. De Crevoisier, R., Bourhis, J., Eschwege, F., Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16 (1998), 3556–3562.
21. Sacco, A.G., Cohen, E.E., Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33:29 (2015 Oct 10), 3305–3313.
22. Young, E.R., Diakos, E., Khalid-Raja, M., Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma: systematic review and meta-analysis. Clin Otolaryngol 40 (2005), 208–218.
23. Buglione, M., Maddalo, M., Bruni, A., Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors. Tumori 101 (2015), 585–592.
24. Colevas, A.D., Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006), 2644–2652.
25. Vermorken, J.B., Mesia, R., Rivera, F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008), 1116–1127.
26. Argiris, A., Li, Y., Forastiere, A., Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101 (2004), 2222–2229.
27. Argiris, A., Li, Y., Murphy, B.A., Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22 (2004), 262–268.
28. Szturz, P., Vermorken, J.B., Treatment of elderly patients with squamous cell carcinoma of the head and neck. Front Oncol, 2016, 1–14.
29. Paleri, V., Wight, R.G., Bradley, P.J., Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 46 (2010), 712–719.
30. Locher, J.L., Bonner, J.A., Carroll, W.R., Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicine. JPEN J Parenter Enteral Nutr 35 (2011), 365–374.
31. Clavel, M., Vermorken, J.B., Cognetti, F., Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5:6 (1994), 521–526.
32. Forastiere, A.A., Metch, B., Schuller, D.E., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:8 (1992), 1245–1251.
33. Jacobs, C., Lyman, G., Velez-García, E., A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:2 (1992), 257–263.
34. Hitt, R., Irigoyen, A., Cortes-Funes, H., Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23:4 (2012), 1016–1022.
35. Ferris, R.L., Blumenschein, G., Gillison, M.L., Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:19 (2016), 1856–1867.
36. Warren, S., Gates, O., Multiple primary malignant tumors: a survey of the literature and statistical study. Am J Cancer 16 (1932), 1358–1414.
37. Curtis, R.E., Freedman, D.M., Ron, E., New malignancies among cancer survivors: SEER cancer registries, 1973–2000. 2006, National Cancer Institute, Bethesda, MD, 9–14.
38. León, X., Quer, M., Burgués, J., Second neoplasm in patients with head and neck cancer. Head Neck 21:3 (1999), 204–210.
39. Garavello, W., Ciardo, A., Gaini, R.M., Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:7 (2006), 762–766.
40. León, X., Martínez, V., Quer, M., Second, third, and fourth head and neck tumors. A progressive decrease in survival. Head Neck 34:12 (2012), 1716–1719.
41. León, X., Martínez, V., Quer, M., Risk of third and fourth tumors in patients with head and neck cancer. Head Neck 32:11 (2010), 1467–1472.
42. Morris, L.G., Sikora, A.G., Ganly, I., Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 20; 29:6 (2011), 739–746.
43. National Lung Screening Trial Research, T., Aberle, D.R., Adams, A.M., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
44. National Comprehensive Cancer Network: Lung Cancer. V1.2017 < http://oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf>.
45. Midthun, D.E., Screening for lung cancer. Clin Chest Med 32 (2011), 659–668.
46. Haerle, S.K., Strobel, K., Stoeckli, S.J., F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck 32:3 (2010), 319–325.
47. Schwartz, L.H., Ozsahin, M., Zhang, G.N., Synchronous and metachronous head and neck carcinomas. Cancer 74:7 (1994), 1933–1938.
48. Wong, L.Y., Wei, W.I., Yuen, A.P., Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 25:11 (2003), 953–959.
49. León, X., Pedemonte, G., Quer, M., Elective treatment of the neck for second primary tumors of the head and neck. Eur Arch Otorhinolaryngol 271:5 (2014), 1187–1190.
50. Goldstein, D.P., Karnell, L.H., Funk, G.F., Outcomes following reirradiation of patients with head and neck cancer. Head Neck 30 (2008), 765–770.
51. Stevens, K.R., Britsch, A., Moss, W.T., High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 29 (1994), 687–698.
52. Galloway, T.J., Ridge, J.A., Management of squamous cancer metastatic to cervical nodes with an unknown primary site. J Clin Oncol 33:29 (2015), 3328–3337.
53. Grau, C., Johansen, L.V., Jakobsen, J., Cervical lymph node metastases from unknown primary tumours: results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 55 (2000), 121–129.
54. Jones, A.S., Cook, J.A., Phillips, D.E., et al. Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer 72 (1993), 1756–1761.
55. Cianchetti, M., Mancuso, A.A., Amdur, R.J., Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 119 (2009), 2348–2354.
56. Johansen, J., Buus, S., Loft, A., Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor: results from the DAHANCA-13 study. Head Neck 30 (2008), 471–478.
57. Motz, K., Qualliotine, J.R., Fakhry, C., Changes in unknown primary squamous cell carcinoma of the head and neck at initial presentation in the era of human papillomavirus. JAMA Otolaryngol–Head Neck Surg 142:3 (2016), 223–228.
58. Keller, L.M., Galloway, T.J., Holdbrook, T., P16 status, pathologic and clinical characteristics, biomolecular signature, and long term outcomes in unknown primary carcinomas of the head and neck. Head Neck 36 (2014), 1677–1684.
59. Lee, W.Y., Hsiao, J.R., Jin, Y.T., Epstein-Barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: an aid for differentiating the primary site. Head Neck 22 (2000), 336–340.
60. Koch, W.M., Bhatti, N., Williams, M.F., et al. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 124 (2001), 331–333.
61. Cosmidis, A., Rame, J.P., Dassonville, O., T1–T2 NO oropharyngeal cancers treated with surgery alone: a GETTEC study. Eur Arch Otorhinolaryngol 261 (2004), 276–281.
62. Waltonen, J.D., Ozer, E., Schuller, D.E., et al. Tonsillectomy vs. deep tonsil biopsies in detecting occult tonsil tumors. Laryngoscope 119 (2009), 102–106.
63. Waltonen, J.D., Ozer, E., Hall, N.C., Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup. Arch Otolaryngol Head Neck Surg 135 (2009), 1024–1029.
64. Kim, S.H., Koo, B.S., Kang, S., HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 120 (2007), 1418–1425.
65. Iganej, S., Kagan, R., Anderson, P., Metastatic squamous cell carcinoma of the neck from an unknown primary: management options and patterns of relapse. Head Neck 24 (2002), 236–246.
66. Coster, J.R., Foote, R.L., Olsen, K.D., Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys 23 (1999), 743–749.
67. Fakhry, C., Westra, W.H., Li, S., Improved survival of patients with human papillomavirus positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008), 261–269.
68. Chung, C.H., Zhang, Q., Kong, C.S., P16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32:35 (2014), 3930–3938.
69. Cooper, J.S., Pajak, T.F., Forastiere, A.A., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004), 1937–1944.
70. Bernier, J., Cooper, J.S., Lefèbvre, J.L., Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:10 (2005), 843–850.
71. Chen, A.M., Farwell, D.G., Lau, D.H., Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?. Int J Radiat Oncol Biol Phys 81 (2001), 346–352.
72. Aroisio, A.D., Pignataro, L., Garavello, W., Neck Lymph node metastases from unknown primary. Cancer Treat Rev 53 (2016), 1–9.
73. Lou, J., Wang, S., Guo, L., Squamous cell carcinoma of cervical lymph nodes from an unknown primary site: The impact of neck dissection. J Cancer Res Ther 11:Suppl. 2 (2015), C161–C167.
74. Strojan, P.1., Ferlito, A., Barnes, L., Contemporary management of lymph node metastases from an unknown primary to the neck: II. A review of therapeutic options. Head Neck 35:2 (2013), 286–293.
75. Reddy, S.P., Marks, J.E., Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation. Int J Radiat Oncol Biol Phys 37 (1997), 797–802.
76. Sher, D.J., Balboni, T.A., Haddad, R.I., Efficacy and toxicity of chemoradiotherapy using intensity modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys 80 (2011), 1405–1411.
77. Marcial-Vega, V.A., Cardenes, H., Perez, C.A., Cervical metastases from unknown primaries: radiotherapeutic management and appearance of subsequent primaries. Int J Radiat Oncol Biol Phys 19 (1990), 919–928.
78. Sinnathamby, K., Peters, L.J., Laidlaw, C., et al. The occult head and neck primary: to treat or not to treat?. Clin Oncol (R Coll Radiol) 9 (1997), 322–329.